← Back to Clinical Trials
Recruiting NCT06601569

NCT06601569 Predictors of Range of Motion and Balance Abnormalities in Children Diagnosed with Cerebral Palsy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06601569
Status Recruiting
Phase
Sponsor Cairo University
Condition Cerebral Palsy
Study Type OBSERVATIONAL
Enrollment 120 participants
Start Date 2024-08-01
Primary Completion 2025-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Months
Max Age 5 Years
Study Type OBSERVATIONAL
Interventions
balance and range of motion

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 120 participants in total. It began in 2024-08-01 with a primary completion date of 2025-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

1. To better understand the factors that contribute to ROM abnormalities in children diagnosed with CP. 2. To describe the distribution of primary (muscle tone and postural stability)and secondary impairments (ROM and functional muscle strength) across the gross motor spectrum measured by GMFCS scores. 3. To evaluate the effects of primary and secondary impairments on gross functional outcome in children with spastic CP. 4. To find any possible correlation between clinical variables.

Eligibility Criteria

Inclusion Criteria: * only children with clinical diagnosis of cerebral palsy , who were receiving physiotherapy services at the paediatric out-patient clinic of Faculty of Physical Therapy, Cairo University for a minimum of six months regularly. Exclusion Criteria: * Children were excluded if they had one or more of the following: behavioral issues, a history of persistent heart or chest disease, significant visual or auditory impairment, botulinum toxin injection at last six months prior to the study.

Contact & Investigator

Central Contact

ahmed fekry salman

✉ a.salman@ammanu.edu.jo

📞 +201067873174

Frequently Asked Questions

Who can join the NCT06601569 clinical trial?

This trial is open to participants of all sexes, aged 18 Months or older, up to 5 Years, studying Cerebral Palsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06601569 currently recruiting?

Yes, NCT06601569 is actively recruiting participants. Contact the research team at a.salman@ammanu.edu.jo for enrollment information.

Where is the NCT06601569 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT06601569 clinical trial?

NCT06601569 is sponsored by Cairo University. The trial plans to enroll 120 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology